AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12355581 — intervention group
Group type: COMPARATOR
Intervention: Glucophage (Lipha Pharmaceutical Industries, France)
Number of subjects: 24
Study 10418540 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride 50 mg (cycle 1)
Number of subjects: 57
Study 10418540 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride 100 mg (cycle 2)
Number of subjects: 57
Study 10418540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 7743984 — intervention group
Group type: COMPARATOR
Intervention: Cycling (CYC)
Number of subjects: 24
Study 7743984 — intervention group
Group type: COMPARATOR
Intervention: Running (RUN)
Number of subjects: 24
Study 7743984 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat/low-carbohydrate foods (after CYC or RUN)
Number of subjects: 24
Study 7743984 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat/high-carbohydrate foods (after CYC or RUN)
Number of subjects: 24
Study 2153765 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV-HEM chemotherapy
Number of subjects: 577
Study 2153765 — intervention group
Group type: COMPARATOR
Intervention: CAV chemotherapy
Number of subjects: 577
Study 2153765 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV maintenance therapy
Number of subjects: 577
Study 2153765 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV-HEM with no maintenance therapy
Number of subjects: 577
Study 2153765 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy
Number of subjects: 577
Study 7387765 — intervention group
Group type: EXPERIMENTAL
Intervention: CEX (cephalexin)
Number of subjects: 12
Study 7387765 — intervention group
Group type: EXPERIMENTAL
Intervention: CCL (cefaclor)
Number of subjects: 12
Study 7387765 — intervention group
Group type: EXPERIMENTAL
Intervention: CDX (cefadroxil)
Number of subjects: 12
Study 7387765 — intervention group
Group type: EXPERIMENTAL
Intervention: CEX (cephalexin) during breakfast
Number of subjects: 12
Study 7387765 — intervention group
Group type: EXPERIMENTAL
Intervention: CDX (cefadroxil) during breakfast
Number of subjects: 12
Study 31851833 — intervention group
Group type: EXPERIMENTAL
Intervention: Instagram abstention for one week (intervention group)
Number of subjects: 80
Study 31851833 — intervention group
Group type: COMPARATOR
Intervention: Instagram usage (control group)
Number of subjects: 80
Study 28737452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation program (1-hour sessions weekly for 8 weeks)
Number of subjects: 60
Study 28737452 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (relaxation techniques weekly)
Number of subjects: 60
Study 28737452 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 27077277 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR‐T reminder at index clinic (IC)
Number of subjects: 8804
Study 27077277 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR‐T reminder at replication clinic (RC)
Number of subjects: 8804
Study 27077277 — intervention group
Group type: COMPARATOR
Intervention: No reminder at index clinic (IC)
Number of subjects: 8804
Study 27077277 — intervention group
Group type: COMPARATOR
Intervention: No reminder at replication clinic (RC)
Number of subjects: 8804
Study 27077277 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for missed appointments
Number of subjects: 8804
Study 25015615 — intervention group
Group type: COMPARATOR
Intervention: Single dose (0.4 mg tamsulosin)
Number of subjects: 70
Study 25015615 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose (0.4 mg tamsulosin + 10 mg alfuzosin)
Number of subjects: 70
Study 22441634 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200μg once daily
Number of subjects: 50
Study 22441634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22441634 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 50
Study 20423436 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral education
Number of subjects: 63
Study 20423436 — intervention group
Group type: EXPERIMENTAL
Intervention: Video education
Number of subjects: 63
Study 18671885 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxpentifylline (400 mg daily)
Number of subjects: 0
Study 18671885 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet daily)
Number of subjects: 0
Study 15954959 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP (5 cmH(2)O)
Number of subjects: 20
Study 15954959 — intervention group
Group type: COMPARATOR
Intervention: ZPEEP (no PEEP)
Number of subjects: 20
Study 15954959 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 15954959 — intervention group
Group type: COMPARATOR
Intervention: Baseline values in CVP and MAP
Number of subjects: 20
Study 19753737 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexpanthenol-containing cream
Number of subjects: 0
Study 19753737 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 0
Study 10333183 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Vision Functional Status Evaluation (LVFSE)
Number of subjects: 155
Study 10333183 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported task performance difficulty
Number of subjects: 155
Study 8529437 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-a-day isepamicin combined with piperacillin
Number of subjects: 34
Study 8529437 — intervention group
Group type: COMPARATOR
Intervention: Twice-a-day combined administration
Number of subjects: 34
Study 8529437 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen
Number of subjects: 34
Study 2028709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytidine 5'-diphosphocholine (2 g iv infusion)
Number of subjects: 11
Study 2028709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytidine 5'-diphosphocholine + GHRH
Number of subjects: 11
Study 2028709 — intervention group
Group type: COMPARATOR
Intervention: GHRH alone
Number of subjects: 11
Study 6987042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephradine given twice daily (70 patients)
Number of subjects: 131
Study 6987042 — intervention group
Group type: COMPARATOR
Intervention: Cephradine given four times daily (61 patients)
Number of subjects: 131
Study 30299258 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 69
Study 30299258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 28661773 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisted sprint swim training
Number of subjects: 24
Study 28661773 — intervention group
Group type: COMPARATOR
Intervention: Nonresisted sprint swim training
Number of subjects: 24
Study 27883295 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB11 rs7602171G>A
Number of subjects: 74
Study 27883295 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTP1 rs1799811C>T
Number of subjects: 74
Study 27883295 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC5A6 rs1395
Number of subjects: 74
Study 27883295 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB4 rs2302387C>T
Number of subjects: 74
Study 27883295 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCC5 rs939339A>G
Number of subjects: 74
Study 25125580 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐05105679 (600 mg)
Number of subjects: 0
Study 25125580 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐05105679 (900 mg)
Number of subjects: 0
Study 25125580 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone (20 mg)
Number of subjects: 0
Study 23137206 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 44
Study 23137206 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 44
Study 23137206 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT)
Number of subjects: 44
Study 23137206 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 44
Study 20711603 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group at neck resting position (NRT)
Number of subjects: 30
Study 20711603 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group at 20° neck flexion position (NFT)
Number of subjects: 30
Study 20711603 — intervention group
Group type: COMPARATOR
Intervention: Untrained group
Number of subjects: 30
Study 18928997 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamin C 1000 mg and vitamin E 400 IU)
Number of subjects: 739
Study 18928997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 739
Study 15834703 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-enhancing (IE) enteral nutrition
Number of subjects: 38
Study 15834703 — intervention group
Group type: COMPARATOR
Intervention: Non-immune-enhancing (NIE) enteral nutrition
Number of subjects: 38
Study 15834703 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IE and NIE)
Number of subjects: 38
Study 12510551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial arm positioning (n = 31)
Number of subjects: 86
Study 12510551 — intervention group
Group type: COMPARATOR
Intervention: Caudal arm positioning (n = 55)
Number of subjects: 86
Study 9822137 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 470
Study 9822137 — intervention group
Group type: COMPARATOR
Intervention: Nisoldipine
Number of subjects: 470
Study 7854804 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Botox)
Number of subjects: 6
Study 7854804 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study 2491361 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg once daily
Number of subjects: 257
Study 2491361 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine, 800 mg once daily
Number of subjects: 257
Study 1093984 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone
Number of subjects: 0
Study 1093984 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone valerate
Number of subjects: 0
Study 1093984 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide
Number of subjects: 0
Study 31675553 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory cognitive task presented during the first 8 minutes of Adaptation
Number of subjects: 40
Study 31675553 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory cognitive task presented during the last 8 minutes of Adaptation
Number of subjects: 40
Study 31675553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive task presented during the entire split‐belt Adaptation phase (14 minutes)
Number of subjects: 40
Study 31675553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive task presented during four 2-minute bouts (8 minutes)
Number of subjects: 40
Study 31621819 — intervention group
Group type: EXPERIMENTAL
Intervention: Face images with both surface reflectance and shape information present (reflectance and shape version)
Number of subjects: 195
Study 31621819 — intervention group
Group type: EXPERIMENTAL
Intervention: Face images with shape information removed but surface reflectance present (reflectance version)
Number of subjects: 195
Study 31621819 — intervention group
Group type: EXPERIMENTAL
Intervention: Face images with surface reflectance information removed but shape present (shape version)
Number of subjects: 195
Study 28221056 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + Memory Support (n = 25)
Number of subjects: 48
Study 28221056 — intervention group
Group type: COMPARATOR
Intervention: CT-as-usual (n = 23)
Number of subjects: 48
Study 28221056 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + Memory Support
Number of subjects: 48
Study 25505238 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening at ages 55 to 59 years with two-year intervals
Number of subjects: 0
Study 25505238 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening at short intervals of three years or less
Number of subjects: 0
Study 25505238 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening above age 63 years
Number of subjects: 0
Study 23895087 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU)
Number of subjects: 79
Study 21550950 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir at 50% of intravenous basal insulin requirements
Number of subjects: 82
Study 21550950 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir at 65% of intravenous basal insulin requirements
Number of subjects: 82
Study 21550950 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir at 80% of intravenous basal insulin requirements
Number of subjects: 82
Study 18807247 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta(9)‐THC (0.0286 mg/kg)
Number of subjects: 23
Study 18807247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17114166 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyboard access (active learning)
Number of subjects: 30
Study 17114166 — intervention group
Group type: COMPARATOR
Intervention: Mouse access (passive learning)
Number of subjects: 30
Study 14756616 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic sample of pathological gamblers who had recently quit gambling
Number of subjects: 101
Study 11298545 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (ALA-PDT)
Number of subjects: 88
Study 11298545 — intervention group
Group type: COMPARATOR
Intervention: Cryosurgery
Number of subjects: 88
Study 9539890 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded assessment
Number of subjects: 20
Study 9539890 — intervention group
Group type: COMPARATOR
Intervention: Unblinded assessment
Number of subjects: 20
Study 8290236 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopanpur (EGIS) 3 x 2 for 10 days
Number of subjects: 15
Study 8290236 — intervention group
Group type: COMPARATOR
Intervention: Creon (Kalichemie) 10,000 3 x 2 for 10 days
Number of subjects: 15
Study 2657499 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 40
Study 2657499 — intervention group
Group type: COMPARATOR
Intervention: Cinoxacin
Number of subjects: 40
Study 30336808 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of granisetron (1 mg tablet, twice daily every 12 hours for 5 days)
Number of subjects: 0
Study 30336808 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal delivery of granisetron (34.3 mg/52 cm2 patch for 6 days)
Number of subjects: 0
Study 31933068 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum DSA-TRF
Number of subjects: 581
Study 31933068 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TRF
Number of subjects: 581
Study 31933068 — intervention group
Group type: EXPERIMENTAL
Intervention: GlycoTRF1
Number of subjects: 581
Study 31589634 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the Job Crafting Questionnaire (JCQ)
Number of subjects: 768
Study 28558627 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to a news clip about an Iranian nuclear attack on Israel
Number of subjects: 154
Study 28558627 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exposure to the film)
Number of subjects: 154
Study 27127999 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 10
Study 27127999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23231573 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete abstinence
Number of subjects: 1226
Study 23231573 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional abstinence
Number of subjects: 1226
Study 23231573 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled drinking
Number of subjects: 1226
Study 23231573 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined behavioral intervention
Number of subjects: 1226
Study 23231573 — intervention group
Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 1226
Study 21660397 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (zinc acetate syrup)
Number of subjects: 98
Study 21660397 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin B-complex syrup)
Number of subjects: 98
Study 21660397 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 98
Study 21660397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 18377135 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterargument appeal
Number of subjects: 0
Study 18377135 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional appeal
Number of subjects: 0
Study 18377135 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivating action appeal
Number of subjects: 0
Study 18377135 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance appeal
Number of subjects: 0
Study 17213598 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 7.5 mg bupivacaine + 5 microg sufentanil + 10% glucose
Number of subjects: 90
Study 17213598 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 7.5 mg bupivacaine + 7.5 microg sufentanil + 10% glucose
Number of subjects: 90
Study 17213598 — intervention group
Group type: COMPARATOR
Intervention: Group C: 15 mg bupivacaine + 10% glucose
Number of subjects: 90
Study 11818299 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidrug public service announcements (PSAs)
Number of subjects: 3608
Study 11818299 — intervention group
Group type: COMPARATOR
Intervention: Control condition (non-drug-related television program)
Number of subjects: 3608
Study 11818299 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidrug PSAs
Number of subjects: 3608
Study 10430716 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (20 ppm delivered during inspiration)
Number of subjects: 16
Study 10430716 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (16 micrograms/kg/min)
Number of subjects: 16
Study 10430716 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (to obtain a 3 mm Hg rise in mean pulmonary arterial pressure)
Number of subjects: 16
Study 10430716 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine + Inhaled NO
Number of subjects: 16
Study 10430716 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate + Inhaled NO
Number of subjects: 16
Study 10430716 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate + Norepinephrine + Inhaled NO
Number of subjects: 16
Study 7548461 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Number of subjects: 27
Study 7548461 — intervention group
Group type: EXPERIMENTAL
Intervention: Dim light therapy
Number of subjects: 27
Study 2144835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (100 mg/year of age up to a maximum of 1.5 g/day)
Number of subjects: 35
Study 2144835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 2144835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Number of subjects: 35
Study 6996121 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone‐releasing hormone (LH‐RH) 500 micrograms 8‐hourly
Number of subjects: 5
Study 6996121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 6361311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil granules (CDX)
Number of subjects: 0
Study 6361311 — intervention group
Group type: COMPARATOR
Intervention: Long-acting cephalexin granules (L-CEX)
Number of subjects: 0
Study 30286416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg over 45 minutes)
Number of subjects: 26
Study 30286416 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 26
Study 30286416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 26
Study 30286416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 29329498 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (n=11)
Number of subjects: 303
Study 29329498 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (n=21)
Number of subjects: 303
Study 29329498 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotic subgroup (n=32)
Number of subjects: 303
Study 29329498 — intervention group
Group type: COMPARATOR
Intervention: Non-psychotic subgroup
Number of subjects: 303
Study 27431306 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily nasal saline irrigation supported by a demonstration video
Number of subjects: 871
Study 27431306 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily steam inhalation
Number of subjects: 871
Study 27431306 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 871
Study 27431306 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with both interventions
Number of subjects: 871
Study 25080906 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-balanced ultrafiltration with modified ultrafiltration (Z+M group)
Number of subjects: 60
Study 25080906 — intervention group
Group type: COMPARATOR
Intervention: Zero-balanced ultrafiltration (Z group)
Number of subjects: 60
Study 25080906 — intervention group
Group type: COMPARATOR
Intervention: Modified ultrafiltration (M group)
Number of subjects: 60
Study 22040532 — intervention group
Group type: EXPERIMENTAL
Intervention: SABA purchased with prescription
Number of subjects: 316
Study 22040532 — intervention group
Group type: COMPARATOR
Intervention: SABA purchased without prescription
Number of subjects: 316
Study 22040532 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti‐inflammatory asthma medication
Number of subjects: 316
Study 20307568 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical tests (FIT)
Number of subjects: 404
Study 20307568 — intervention group
Group type: COMPARATOR
Intervention: Guaiac-based fecal occult blood tests (gFOBT)
Number of subjects: 404
Study 17508621 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodisinfection (PD) alone
Number of subjects: 33
Study 17508621 — intervention group
Group type: COMPARATOR
Intervention: Scaling and Root Planing (SRP) alone
Number of subjects: 33
Study 17508621 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP combined with Photodisinfection (SRP + PD)
Number of subjects: 33
Study 16285996 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal 300 mg/day
Number of subjects: 60